PRKCA

(redirected from Pkc-alpha)

PRKCA

A gene on chromosome 17q22-q23.2 that encodes a calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase, which up- or downregulates cell proliferation, apoptosis, differentiation, migration and adhesion; tumourigenesis; cardiac hypertrophy; angiogenesis; and platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signalling cascades involving MAPK1/3 and RAP1GA.
References in periodicals archive ?
Oxalate induced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells.
ISIS 3521, an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is also in Phase III trials for Crohn's disease.
Inulin stimulates NO synthesis via activation of PKC-alpha and protein tyrosine kinase, resulting in the activation of NF-kappaB by IFN-gamma-primed RAW 264.7 cells.
Affinitak (formerly called LY900003 and ISIS 3521), an inhibitor of PKC-alpha, is in Phase III development for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease.
Affinitak (formerly called LY900003 and ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease.
Affinitac (formerly called LY900003 and ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease.
PKC-alpha works with glutamate and norepinephrine to create those changes.
Our findings indicate that the PKC-alpha enzyme tells the nerve cells in the brain that these two chemicals have arrived together.